Mylan Settles Fortamet Patent Suit With Shionogi, Andrx

Law360, Los Angeles (March 13, 2013, 5:06 PM EDT) -- Mylan Pharmaceuticals Inc. has settled a patent infringement suit brought by Shionogi Inc. and Andrx Corp. over Mylan's bid to develop a generic equivalent of Shionogi's blood glucose drug Fortamet, Mylan announced Wednesday.

The settlement ends a dispute that dates back to February 2010, when Andrx, which holds the patents for 500-milligram and 1,000-milligram extended-release metformin hydrochloride tablets, and Shionogi, which markets the tablets under the Fortamet brand, sued Mylan for seeking to manufacture and sell a generic version of the drug prior to the expiration...
To view the full article, register now.